Research analysts at HC Wainwright decreased their Q3 2025 earnings estimates for shares of Bright Minds Biosciences in a ...

Analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for shares of Axsome Therapeutics in a research note issued to investors on Thursday, February 20th. HC Wainwright analyst R ...

H.C. Wainwright analyst Mike Colonnese notes that Coinbase (COIN) announced that the Securities and Exchange Commission has agreed to dismiss ...

H.C. Wainwright raised the firm’s price target on Axsome Therapeutics (AXSM) to $200 from $190 and keeps a Buy rating on the shares following ...

H.C. Wainwright analyst Scott Buc adjusted the price target for Neurotrope (NASDAQ:NTRP) shares, raising it to $5.00 from the previous $2.50, while maintaining a Neutral rating on the stock. The ...

H.C. Wainwright reiterated a Buy rating and a price target of $18.00 on Enanta Pharmaceuticals (NASDAQ:ENTA) shares, significantly above the current price of $4.90. The stock is trading near its ...

Number 1 Investment Bank for Confidentially Marketed Public Offerings, Registered Direct, Private Placement, and At-the-Market (ATM) Offerings H.C. Wainwright & Co., LLC, announced its #1 Ranking ...

will participate in the H.C. Wainwright 3 rd Annual Cell Therapy Virtual Conference on Tuesday, February 25 at 10:30 am ET. (PRNewsfoto/CARISMA Therapeutics Inc.) An audio webcast of the event ...

Thursday, H.C. Wainwright reaffirmed a Buy rating on Precision BioSciences Inc . (NASDAQ:DTIL) with a steady price target of $60.00, significantly above the current trading price of $5.65. The ...

In 2024 H.C. Wainwright also held the top position in PlacementTracker's Market League Tables for At-the-Market (ATM) Offerings representing 72 transactions. In addition to presently serving as ...